- Trials with a EudraCT protocol (158)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
158 result(s) found for: Crohn's Disease AND Colitis.
Displaying page 5 of 8.
| EudraCT Number: 2014-001919-39 | Sponsor Protocol Number: 48890 | Start Date*: 2014-08-27 |
| Sponsor Name:Erasmus MC | ||
| Full Title: Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study | ||
| Medical condition: Inflammatory bowel disease | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001410-10 | Sponsor Protocol Number: GIS-SUSANTI-TNF-2015 | Start Date*: 2016-06-22 | |||||||||||
| Sponsor Name:Fundación de Investigación Biomédica Hospital Universitario de la Princesa | |||||||||||||
| Full Title: Anti-TNF discontinuation in patients with inflammatory bowel disease: Multicentre, prospective, randomized clinical trial and economic evaluation | |||||||||||||
| Medical condition: Inflammatory bowel disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001546-33 | Sponsor Protocol Number: RHMMED1526 | Start Date*: 2018-07-11 | |||||||||||
| Sponsor Name:University Southampton Hospital NHS Foundation Trust | |||||||||||||
| Full Title: IBD Biosimilar to Biosimilar Infliximab Switching Study | |||||||||||||
| Medical condition: Inflammatory Bowel Disease in particular Crohn's Disease and Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-003966-34 | Sponsor Protocol Number: A12-771 | Start Date*: 2011-12-06 |
| Sponsor Name:Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) | ||
| Full Title: The ADACAL Study: cAlprotectin and hsCRP as markers of a new Diagnostic-therapeutic strAtegy that assesses muCosal Activity to individuaLize treatment and improve the prognosis of patients with Cro... | ||
| Medical condition: Crohn's disease (CD) is an inflammatory disease of the intestines that primarily causes abdominal pain, diarrhea, vomiting, or weight loss. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004325-10 | Sponsor Protocol Number: ME/2005/2018 | Start Date*: 2005-08-16 |
| Sponsor Name:United Bristol Healthcare Trust | ||
| Full Title: Evaluate Whether A Short Course Of Once Weekly Risedronate Prevents Bone Loss Following High-Dose Steroid Therapy For An Acute Exacerbation Of Inflammatory Bowel Disease. | ||
| Medical condition: We aim to determine whether Risedronate is effective at preventing acute bone loss associated with a short course of corticosteroid (CS) therapy to treat exacerbations of inflammatory bowel disease... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-022758-18 | Sponsor Protocol Number: CNTO1275CRD3001 | Start Date*: 2011-08-24 | |||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severe... | |||||||||||||
| Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) GB (Completed) BE (Completed) CZ (Completed) IS (Completed) IE (Completed) ES (Completed) DK (Completed) HU (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-007519-34 | Sponsor Protocol Number: FAST VERSION | Start Date*: 2009-04-17 |
| Sponsor Name:University of Leuven Hospitals, Division of Gastroenterology | ||
| Full Title: Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST | ||
| Medical condition: This is a open label, prospective, multicenter trial in patients recieving one hour infusions of infliximab (i.e. Remicade)as part of their daily practice. Main objective: Is to assess the tolerab... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002640-27 | Sponsor Protocol Number: GED-301-01-11 | Start Date*: 2011-07-14 | |||||||||||
| Sponsor Name:GIULIANI | |||||||||||||
| Full Title: A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis) | |||||||||||||
| Medical condition: ACTIVE CROHN'S DISEASE | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004463-25 | Sponsor Protocol Number: RHMMED1716 | Start Date*: 2020-12-15 |
| Sponsor Name:University Hospital Southampton NHS Trust | ||
| Full Title: SWitching InflixiMab to SUbcut from Intravenous Therapy | ||
| Medical condition: Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-002369-17 | Sponsor Protocol Number: 2021-01 | Start Date*: 2021-07-22 |
| Sponsor Name:GETAID | ||
| Full Title: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial. | ||
| Medical condition: Crohn's disease patients having an i2 endoscopic postoperative recurrence 6-12 months after ileocolonic anastomosis. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-002783-33 | Sponsor Protocol Number: C13007 | Start Date*: 2009-03-02 | |||||||||||
| Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise... | |||||||||||||
| Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-002211-65 | Sponsor Protocol Number: GIS-2021-JAKihemo | Start Date*: 2021-08-13 | |||||||||||||||||||||
| Sponsor Name:Fundación Española de Gastroenterología | |||||||||||||||||||||||
| Full Title: EFFECT OF TOFACITINIB ON COAGULATION AND PLATELET FUNCTION, AND ITS ROLE IN THROMBOEMBOLIC EVENTS | |||||||||||||||||||||||
| Medical condition: ulcerative colitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-001377-28 | Sponsor Protocol Number: 27577 | Start Date*: 2008-06-11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Merck Serono International S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-005086-39 | Sponsor Protocol Number: BT-11-201 | Start Date*: 2019-10-28 | ||||||||||||||||
| Sponsor Name:Landos Biopharma Inc. | ||||||||||||||||||
| Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis | ||||||||||||||||||
| Medical condition: Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifesta... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Completed) PL (Completed) HR (Completed) BG (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-004219-29 | Sponsor Protocol Number: 140041 | Start Date*: 2020-04-21 |
| Sponsor Name:Amsterdam UMC | ||
| Full Title: “Personalized AZithromycin/metronidAZole, in combination with standard induction therapy, to achieve a fecal microbiome community structure and metagenome changes associated with sustained remissio... | ||
| Medical condition: Crohn's Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001924-40 | Sponsor Protocol Number: GED-0301-CD-003 | Start Date*: 2017-02-21 | |||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||
| Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with act... | |||||||||||||
| Medical condition: Active Crohn's disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-004313-15 | Sponsor Protocol Number: NI-0401-01 | Start Date*: 2006-07-14 |
| Sponsor Name:NovImmune S.A. | ||
| Full Title: A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease | ||
| Medical condition: Moderate to Severe Active Crohn´s Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-005059-10 | Sponsor Protocol Number: Trp-IBD | Start Date*: 2018-09-14 |
| Sponsor Name:Ghent University Hospital | ||
| Full Title: Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores | ||
| Medical condition: Inflammatory Bowel Disease (IBD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-006881-19 | Sponsor Protocol Number: TV48574-IMM-20036 | Start Date*: 2022-12-21 | ||||||||||||||||
| Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||||||||||||
| Full Title: A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerat... | ||||||||||||||||||
| Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-004012-10 | Sponsor Protocol Number: MODIFI | Start Date*: 2021-06-17 |
| Sponsor Name:UZ Leuven | ||
| Full Title: Model-informed infliximab dose de-escalation following earlier dose escalation in adult patients with inflammatory bowel diseases | ||
| Medical condition: Inflammatory bowel diseases - Crohn's disease - ulcerative colitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.